NCT03001843 is a Phase 4 clinical trial of Ketamine in Laparoscopic Gastric Bypass, sponsored by University of Florida.

Who is sponsoring NCT03001843?

NCT03001843 is sponsored by University of Florida.

What drugs are being tested in NCT03001843?

Interventions in NCT03001843: Ketamine, Narcotics, pain scale.

What condition does NCT03001843 study?

NCT03001843 studies Laparoscopic Gastric Bypass, Obesity, Pain, Postoperative.

Is NCT03001843 still recruiting?

NCT03001843 is currently completed. Last updated 9 March 2021.

Are results published for NCT03001843?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-03-09 · How we verify

NCT03001843

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ketamine vs Hydromorphone

Completed Phase 4 Results posted Last updated 9 March 2021

What this trial tests

Phase 4 trial testing Ketamine in Laparoscopic Gastric Bypass in 54 participants. Completed in 21 December 2018.

Timeline

22 February 2017

Primary endpoint
21 December 2018

21 December 2018

Quick facts

Lead sponsor	University of Florida
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	other
Enrollment	54
Start date	22 February 2017
Primary completion	21 December 2018
Estimated completion	21 December 2018
Sites	1 location across United States

Drugs / interventions tested

Ketamine (ketamine) — full drug profile →
Narcotics — full drug profile →
pain scale

Conditions studied

Laparoscopic Gastric Bypass — all drugs for Laparoscopic Gastric Bypass →
Obesity — all drugs for Obesity →
Pain, Postoperative — all drugs for Pain, Postoperative →

Sponsor

University of Florida

Who can join

Adults 18 to 65, any sex, with Laparoscopic Gastric Bypass or Obesity. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Pain Measured Based on Pain Medication Used on a Scale of 0-10 Primary · 48 hours

Used to translate the dose and route of each of the opioids the patient has received over the last 48 hours to a parenteral morphine equivalent using a standard conversion table. SD standard deviation, mg: milligrams, pain measured on a 0-10 scale

Group	Value	95% CI
Non-Ketamine	1.3	± 2.2
Ketamine	0.7	± 1.5

Length of Stay (Hours) Secondary · 48 hours

Length of stay compared between the 2 groups in hours.

Group	Value	95% CI
Non-Ketamine	43.6	± 20.6
Ketamine	39.8	± 14.5

Sponsor's own description

This study will help to determine if investigators can minimize narcotic use in laparoscopic gastric bypass patients while maintaining adequate pain control. This will allow investigators to minimize the negative side effects of narcotics which is a goal in this population.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Ketamine

Trials testing the same drug.

NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
NCT06963294 — Ketamine and Dexmedetomidine for Delirium in Joint Arthroplasty · NA · not yet recruiting
NCT07294092 — Ketamine and Propofol NeuroImaging · EARLY_PHASE1 · recruiting
NCT07197684 — Ultrasound Guided Pecs Block and Ketamine Infusion for Preventing Chronic Pain in Patients Undergoing Breast Cancer Surg · NA · not yet recruiting
NCT06231563 — Ketamine for Veterans With Parkinson's Disease · Phase 2 · recruiting

Other University of Florida trials

Trials by the same sponsor.

NCT03429413 — Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial · NA · not yet recruiting
NCT06127550 — taVNS for Letter Learning in Dyslexia · NA · suspended
NCT07507214 — Optimized, Neuroplasticity-Enhanced-Depression (ONE-D) Transcranial Magnetic Stimulation (TMS) Treatment for Female Athl · Phase 2, PHASE3 · not yet recruiting
NCT07492316 — RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB) · Phase 1 · not yet recruiting
NCT06670794 — Using Ecological Momentary Data to Inform a Web Intervention for Romantic Partners Concerned About Their Loved Ones' Dri · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03001843 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Florida
Last refreshed: 9 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03001843.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing